An 88 year-old female presented with progressive shortness of breath – NYHA class III, with a history of hypertension, chronic diastolic HF, COPD and s/p BAV on 7/2/15. TTE revealed severe AS, peak/mean aortic gradient = 65/44 mmHg, AVA = 0.6 sq cm, aortic peak velocity = 4 m/sec and LVEF 65%. CT angio showed minimum diameters of 0.4 x 0.7 cm for right and 0.6 x 0.6 cm for the left common femoral arteries and aortic annulus of 2.5 x 2.1 cm (average 2.3). The STS risk mortality is 5.15 and the Logistic Euroscore mortality is 12.81. Patient was determined to be extreme risk for surgical AVR due to advanced age and marked, generalized frailty. Patient is now planned for CoreValve Evolut R TAVR (26mm) via percutaneous femoral access under conscious sedation.
Mitral ViV TMVR using SAPIEN-3 Valve – May 2019
81 year old female presents with worsening dyspnea on minimal exertion (NYHA class III) over the last few months. Her past medical history is significant for rheumatic heart disease with severe MR and MS s/p bioprosthetic MVR with 29 mm porcine valve (Biocor, St. Jude Medical) along with MAZE procedure in 2007. She also has […]
Valve-in-Valve TAVR with 26mm SAPIEN-3 – March 2019
79 year old man presents with worsening exertional dyspnea (NYHA Class III) for the last 3 months. Patient has required multiple recent admissions to hospital with CHF exacerbation requiring IV diuretics. Past medical history is significant for symptomatic bicuspid aortic valve with dilated ascending aorta s/p Bentall procedure (2011) with 25 mm Carpentier-Edwards pericardial valve […]
Valve-in-Valve TAVR with 29mm Evolut-R CoreValve – January 2019
79 year old man presents with progressive exertional dyspnea (NYHA Class III) for the last 2 months.